Letko Brosseau & Associates Inc. Decreases Stake in Moderna, Inc. $MRNA

Letko Brosseau & Associates Inc. lessened its stake in Moderna, Inc. (NASDAQ:MRNA) by 20.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 726,440 shares of the company’s stock after selling 186,950 shares during the quarter. Letko Brosseau & Associates Inc.’s holdings in Moderna were worth $21,423,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in MRNA. AQR Capital Management LLC purchased a new position in shares of Moderna in the 1st quarter valued at about $415,000. NewEdge Advisors LLC lifted its stake in Moderna by 732.7% during the first quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock worth $328,000 after purchasing an additional 10,185 shares during the last quarter. United Services Automobile Association purchased a new stake in Moderna during the first quarter worth approximately $230,000. Focus Partners Wealth lifted its stake in Moderna by 58.7% during the first quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock worth $668,000 after purchasing an additional 8,706 shares during the last quarter. Finally, American Century Companies Inc. lifted its stake in Moderna by 5.2% during the second quarter. American Century Companies Inc. now owns 48,859 shares of the company’s stock worth $1,348,000 after purchasing an additional 2,410 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MRNA. Citigroup restated a “neutral” rating on shares of Moderna in a research note on Monday, February 16th. Bank of America boosted their target price on Moderna from $32.00 to $34.00 and gave the stock an “underperform” rating in a research note on Monday. Piper Sandler boosted their target price on Moderna from $63.00 to $69.00 and gave the stock an “overweight” rating in a research note on Monday, February 23rd. UBS Group restated a “neutral” rating on shares of Moderna in a research note on Tuesday, May 26th. Finally, Barclays boosted their target price on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 2nd. Two analysts have rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average price target of $36.60.

Insider Transactions at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total transaction of $173,550.00. Following the transaction, the insider owned 67,468 shares of the company’s stock, valued at $3,373,400. The trade was a 4.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $48.40, for a total value of $2,581,462.40. Following the transaction, the president directly owned 1,477,997 shares in the company, valued at approximately $71,535,054.80. This trade represents a 3.48% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 71,752 shares of company stock worth $3,453,843. 10.80% of the stock is currently owned by corporate insiders.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and the University of Oxford received UK authorization to begin a Phase 1/2 study of the investigational mRNA-4194 cancer vaccine for people with Lynch syndrome, a high-risk inherited condition. The move highlights progress in Moderna’s oncology pipeline and could support long-term growth expectations. Article: Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
• Positive Sentiment: Recent coverage around Oxford’s cancer vaccine trials and preventive mRNA approaches has increased investor focus on Moderna’s ability to expand beyond COVID vaccines into cancer prevention, which could be a meaningful future catalyst. Article: Oxford–Moderna Cancer Vaccine Trial To Test Preventive mRNA Approach In High-Risk Patients
• Neutral Sentiment: Moderna’s presentation at the Goldman Sachs Global Healthcare Conference may have offered updates on strategy and pipeline progress, but no major new financial guidance or product approval was highlighted in the headline alone. Article: Moderna, Inc. (MRNA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Reported short interest data showed no meaningful bearish positioning change, so it does not appear to be a major driver for the shares.
• Negative Sentiment: Insider Shannon Thyme Klinger sold 3,471 shares, which can weigh on sentiment even though the sale was tied to tax withholding under a pre-arranged 10b5-1 plan.
• Negative Sentiment: Bank of America raised its price target on Moderna but kept an underperform rating, reinforcing a cautious analyst outlook on the stock.

Moderna Trading Up 0.3%

MRNA opened at $47.73 on Wednesday. The firm has a market cap of $18.94 billion, a price-to-earnings ratio of -5.86 and a beta of 1.05. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $59.55. The business’s 50 day moving average is $49.68 and its two-hundred day moving average is $43.63. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, May 1st. The company reported ($3.40) EPS for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The firm had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative return on equity of 26.64% and a negative net margin of 143.55%.The company’s quarterly revenue was up 260.2% on a year-over-year basis. During the same period last year, the firm earned ($2.52) EPS. On average, research analysts predict that Moderna, Inc. will post -6.51 EPS for the current year.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.